GLP-1 agonists and tirzepatide achieve 1522% weight loss in clinical trials DSMES (Diabetes Self-Management Education and Support): ADA 2026 Recommendation 5.2 provide DSMES at diagnosis, annually, when complications develop, and at life transitions
The Hims decision to launch a knockoff Wegovy pill was a step too far, John Kuckelman, general counsel at Novo, said in an interview
Kaylee Stutts, 30, was originally hesitant about trying a compounded weight-loss drug
Anyone with a previous retina laser, injections, or vitrectomy Anyone told they have bleeding, swelling, or retinopathy Anyone with recent blurred vision, floaters, or distortion Anyone whose diabetes doctor expects a major glucose improvement over a short time Warning Signs to Watch For Starting a GLP-1 drug does not mean you should become fearful of every eye sensation